Home › Compare › AICOF vs JNJ

AICOF vs JNJ: Dividend Comparison 2026

AICOF yields 200000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AICOF wins by $4.911780474428384e+29M in total portfolio value
10 years
AICOF
AICOF
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.911780474428384e+29M
Annual income
$490,695,411,370,591,700,000,000,000,000,000,000.00
Full AICOF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AICOF vs JNJ

📍 AICOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAICOFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AICOF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AICOF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AICOF
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$417,091,099,665,002,940,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AICOF beats the other by $417,091,099,665,002,940,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AICOF + JNJ for your $10,000?

AICOF: 50%JNJ: 50%
100% JNJ50/50100% AICOF
Portfolio after 10yr
$2.455890237214192e+29M
Annual income
$245,347,705,685,295,860,000,000,000,000,000,000.00/yr
Blended yield
99.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AICOF
No analyst data
Altman Z
-22.1
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AICOF buys
0
JNJ buys
0
No recent congressional trades found for AICOF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAICOFJNJ
Forward yield200000.00% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$4.911780474428384e+29M$30.3K ✓
Annual income after 10y$490,695,411,370,591,700,000,000,000,000,000,000.00 ✓$4,689.40
Total dividends collected$4.911464459982279e+29M$15.4K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AICOF vs JNJ ($10,000, DRIP)

YearAICOF PortfolioAICOF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$20,010,700$20,000,000.00$10,592$272.30+$20.00M → AICOF
2$37,424,589,019$37,403,177,570.09$11,289$357.73+$37424.58M → AICOF
3$65,416,215,188,220$65,376,170,877,969.18$12,123$472.89+$65416215.18M → AICOF
4$106,868,230,495,008,900$106,798,235,144,757,520.00$13,141$629.86+$106868230495.00M → AICOF
5$163,172,871,735,896,870,000$163,058,522,729,267,200,000.00$14,408$846.81+$163172871735896.88M → AICOF
6$232,854,599,801,468,860,000,000$232,680,004,828,711,460,000,000.00$16,021$1,151.60+$232854599801468864.00M → AICOF
7$310,570,858,137,017,100,000,000,000$310,321,703,715,229,540,000,000,000.00$18,122$1,588.22+$310570858137017057280.00M → AICOF
8$387,148,154,301,613,200,000,000,000,000$386,815,843,483,406,600,000,000,000,000.00$20,930$2,228.20+$3.871481543016132e+23M → AICOF
9$451,061,749,763,281,040,000,000,000,000,000$450,647,501,238,178,360,000,000,000,000,000.00$24,792$3,191.91+$4.510617497632811e+26M → AICOF
10$491,178,047,442,838,440,000,000,000,000,000,000$490,695,411,370,591,700,000,000,000,000,000,000.00$30,274$4,689.40+$4.911780474428384e+29M → AICOF

AICOF vs JNJ: Complete Analysis 2026

AICOF — Stock

Generative AI Solutions Corp., an artificial intelligence company, focuses on development and commercialization of AI-powered tools and solutions for businesses and consumers across various industries in Canada. The company offers MAI Cloud, a cloud-based database; Remitz, which identifies and submits claims related to medical billing; and Classmate app, which utilizes natural language processing to find answers to educational questions. It also provides AI-powered products and services, including predictive analytics tools, chatbots, and machine learning platforms. In addition, the company is developing Tobacco Titan for the tobacco industry; and Global AI Newswire, which sends real-time press releases of publicly listed companies to users. It serves customers in education, healthcare, finance, and transportation industries. Generative AI Solutions Corp. is headquartered in Vancouver, Canada.

Full AICOF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AICOF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AICOF vs SCHDAICOF vs JEPIAICOF vs OAICOF vs KOAICOF vs MAINAICOF vs ABBVAICOF vs MRKAICOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.